Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
59 hedge funds and large institutions have $87.9M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 10 closing their positions.
599% more call options, than puts
Call options by funds: $468K | Put options by funds: $67K
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
28% more capital invested
Capital invested by funds: $68.5M → $87.9M (+$19.4M)
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
2% more funds holding
Funds holding: 58 → 59 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$18.4M |
| 2 |
DA
DSC Advisors
Chicago,
Illinois
|
+$2.06M |
| 3 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$703K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$491K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$434K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$5.89M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.02M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.55M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.41M |
| 5 |
Millennium Management
New York
|
-$1.37M |
FOMX Hedge Fund Activity: Q3 2019 in Review
59 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q3 2019, worth a combined $87.9M — up 28% from $68.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new FOMX positions and 10 closed out — a net gain of 2 holders — while 22 added to existing stakes and 12 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $18.4M. The largest seller was Franklin Resources, exiting entirely with an estimated $5.89M sold.
- 59 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q3 2019, up from 58 in Q2 2019.
- Funds reported $87.9M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q3 2019, up 28% quarter-over-quarter.
- 12 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q3 2019 and 10 closed out, a net change of +2 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q3 2019 was Perceptive Advisors, an estimated $18.4M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q3 2019 was Franklin Resources, an estimated $5.89M sold.
Based on aggregated 13F filings for Q3 2019.